Cataract — Performance of a Photoscreener for Vision Screening in a Haitian Pediatric Population
Citation(s)
Arnold RW, Armitage MD Performance of four new photoscreeners on pediatric patients with high risk amblyopia. J Pediatr Ophthalmol Strabismus. 2014 Jan-Feb;51(1):46-52. doi: 10.3928/01913913-20131223-02.
Atkinson J, Braddick O, Nardini M, Anker S Infant hyperopia: detection, distribution, changes and correlates-outcomes from the cambridge infant screening programs. Optom Vis Sci. 2007 Feb;84(2):84-96. Review.
Courtright P, Hutchinson AK, Lewallen S Visual impairment in children in middle- and lower-income countries. Arch Dis Child. 2011 Dec;96(12):1129-34. doi: 10.1136/archdischild-2011-300093. Review.
Cummings GE Vision screening in junior schools. Public Health. 1996 Nov;110(6):369-72.
Kedir J, Girma A Prevalence of refractive error and visual impairment among rural school-age children of Goro District, Gurage Zone, Ethiopia. Ethiop J Health Sci. 2014 Oct;24(4):353-8.
Kirk S, Armitage MD, Dunn S, Arnold RW Calibration and validation of the 2WIN photoscreener compared to the PlusoptiX S12 and the SPOT. J Pediatr Ophthalmol Strabismus. 2014 Sep-Oct;51(5):289-92. doi: 10.3928/01913913-20140701-01.
Krumholtz I Results from a pediatric vision screening and its ability to predict academic performance. Optometry. 2000 Jul;71(7):426-30. Erratum in: Optometry. 2000 Aug;71(8):489.
Kvarnström G, Jakobsson P, Lennerstrand G Screening for visual and ocular disorders in children, evaluation of the system in Sweden. Acta Paediatr. 1998 Nov;87(11):1173-9.
Lennerstrand G, Jakobsson P, Kvarnström G Screening for ocular dysfunction in children: approaching a common program. Acta Ophthalmol Scand Suppl. 1995;(214):26-38; discussion 39-40. Review.
Maida JM, Mathers K, Alley CL Pediatric ophthalmology in the developing world. Curr Opin Ophthalmol. 2008 Sep;19(5):403-8. doi: 10.1097/ICU.0b013e328309f180. Review.
Mathers M, Keyes M, Wright M A review of the evidence on the effectiveness of children's vision screening. Child Care Health Dev. 2010 Nov;36(6):756-80. doi: 10.1111/j.1365-2214.2010.01109.x. Review.
Roch-Levecq AC, Brody BL, Thomas RG, Brown SI Ametropia, preschoolers' cognitive abilities, and effects of spectacle correction. Arch Ophthalmol. 2008 Feb;126(2):252-8; quiz 161. doi: 10.1001/archophthalmol.2007.36.
Sharma A, Congdon N, Patel M, Gilbert C School-based approaches to the correction of refractive error in children. Surv Ophthalmol. 2012 May-Jun;57(3):272-83. doi: 10.1016/j.survophthal.2011.11.002. Review.
Silbert DI, Matta NS Performance of the Spot vision screener for the detection of amblyopia risk factors in children. J AAPOS. 2014 Apr;18(2):169-72. doi: 10.1016/j.jaapos.2013.11.019.
US Preventive Services Task Force . Vision screening for children 1 to 5 years of age: US Preventive Services Task Force Recommendation statement. Pediatrics. 2011 Feb;127(2):340-6. doi: 10.1542/peds.2010-3177.
Williams C, Harrad RA, Harvey I, Sparrow JM; ALSPAC Study Team . Screening for amblyopia in preschool children: results of a population-based, randomised controlled trial. ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood. Ophthalmic Epidemiol. 2001 Dec;8(5):279-95.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.